Centessa Pharmaceuticals PLC Sponsored ADR $CNTA is Affinity Asset Advisors LLC’s 7th Largest Position

Affinity Asset Advisors LLC increased its stake in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 133.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,400,000 shares of the company’s stock after purchasing an additional 799,448 shares during the quarter. Centessa Pharmaceuticals makes up approximately 2.9% of Affinity Asset Advisors LLC’s portfolio, making the stock its 7th largest position. Affinity Asset Advisors LLC owned about 0.94% of Centessa Pharmaceuticals worth $55,608,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in CNTA. TD Waterhouse Canada Inc. acquired a new stake in shares of Centessa Pharmaceuticals during the 4th quarter valued at $25,000. Caitong International Asset Management Co. Ltd acquired a new stake in Centessa Pharmaceuticals during the fourth quarter valued at $36,000. T. Rowe Price Investment Management Inc. boosted its position in Centessa Pharmaceuticals by 7,580.0% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock valued at $39,000 after purchasing an additional 1,516 shares during the last quarter. Wells Fargo & Company MN grew its stake in Centessa Pharmaceuticals by 42.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after purchasing an additional 1,008 shares in the last quarter. Finally, Knott David M Jr acquired a new position in Centessa Pharmaceuticals in the 4th quarter worth about $100,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ:CNTA opened at $40.50 on Friday. The firm has a market capitalization of $6.27 billion, a PE ratio of -22.63 and a beta of 1.11. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.23. Centessa Pharmaceuticals PLC Sponsored ADR has a 1-year low of $12.74 and a 1-year high of $40.56. The business’s 50 day moving average is $40.14 and its 200-day moving average is $33.69.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Tuesday, May 5th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.14). Sell-side analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Guggenheim downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 2nd. Needham & Company LLC downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, March 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Monday, April 20th. Leerink Partners cut shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and lifted their target price for the company from $36.00 to $40.00 in a research note on Wednesday, April 1st. Finally, B. Riley Financial cut shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Four research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $41.33.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.